Ann: PharmAust Receives R&D Tax Incentive Refund, page-2

I like the revised wording in the footer.

It provides a clear snapshot of our program and a focus on our future direction :


About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage
biotechnology company developing therapeutics for human and animal health applications. The company is
focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and
proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning
process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is
disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).

PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently
completing a Phase 1 study in patients with MND/ALS. Top-line results are expected to be announced in Q1
CY2024. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the
US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell
Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase
1 oncology clinical study of monepantel in humans and pilot studies in canine cancer